Scholarlink

<p>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised by motor neuron degeneration, muscle weakness, paralysis, and eventual death, with TAR DNA-binding protein 43 (TDP-43) pathology observed in almost all&#xa0;cases. Mouse models based on TDP-43 are thus&#xa0;essential for studying ALS and developing therapeutic approaches. The TDP-43 rNLS8 mouse model expresses a human TDP-43 transgene with a mutated nuclear localization sequence (hTDP-43 ΔNLS), but this&#xa0;is normally suppressed by the presence of doxycycline (Dox). Disease is initiated by removal of Dox,&#xa0;which&#xa0;replicates key ALS features, including TDP-43 pathology, neuromuscular junction denervation, motor neuron loss, and reduced survival. However, this model&#xa0;has a&#xa0;rapid disease progression which&#xa0;limits its use for extended preclinical studies&#xa0;and investigation&#xa0;of&#xa0;early disease mechanisms. To overcome these limitations, we explored whether maintaining low Dox concentrations in the diet (10–20&#xa0;mg/kg) could slow disease progression. Our findings demonstrate that this approach significantly&#xa0;reduced hTDP-43 ΔNLS expression (up to 4.8-fold), which&#xa0;delayed disease onset by four weeks. Disease progression, assessed by rotarod performance, grip strength, and neurological scores, was&#xa0;extended from six to 15&#xa0;weeks, with a threefold increase in survival. Despite slower progression, at the end stage, mice displayed similar levels of&#xa0;neuroinflammation, motor neuron loss, as Dox off mice. These findings highlight slower-progressing TDP-43 rNLS8 mice as a robust model for preclinical and early disease mechanism studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Slower-Progressing TDP-43 rNLS8 Mouse Model for ALS: Implications for Preclinical and Mechanistic Studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月18日

查看全文
  • Cyril Jones Jagaraj,
  • Prachi Mehta,
  • Julie Hunter,
  • Julie D. Atkin

摘要

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised by motor neuron degeneration, muscle weakness, paralysis, and eventual death, with TAR DNA-binding protein 43 (TDP-43) pathology observed in almost all cases. Mouse models based on TDP-43 are thus essential for studying ALS and developing therapeutic approaches. The TDP-43 rNLS8 mouse model expresses a human TDP-43 transgene with a mutated nuclear localization sequence (hTDP-43 ΔNLS), but this is normally suppressed by the presence of doxycycline (Dox). Disease is initiated by removal of Dox, which replicates key ALS features, including TDP-43 pathology, neuromuscular junction denervation, motor neuron loss, and reduced survival. However, this model has a rapid disease progression which limits its use for extended preclinical studies and investigation of early disease mechanisms. To overcome these limitations, we explored whether maintaining low Dox concentrations in the diet (10–20 mg/kg) could slow disease progression. Our findings demonstrate that this approach significantly reduced hTDP-43 ΔNLS expression (up to 4.8-fold), which delayed disease onset by four weeks. Disease progression, assessed by rotarod performance, grip strength, and neurological scores, was extended from six to 15 weeks, with a threefold increase in survival. Despite slower progression, at the end stage, mice displayed similar levels of neuroinflammation, motor neuron loss, as Dox off mice. These findings highlight slower-progressing TDP-43 rNLS8 mice as a robust model for preclinical and early disease mechanism studies.